Page 28 - Read Online

Page 353 Giliberti et al. J Transl Genet Genom 2024;8:340-54 https://dx.doi.org/10.20517/jtgg.2024.41

45. Linhart A, Dostálová G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were
previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis 2023;18:332. DOI
PubMed PMC
46. Bernat J, Holida M, Longo N, et al. eP149: safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: results from
the phase 3, open-label, BRIGHT study. Genet Med 2022;24:S91-2. DOI
47. Germain DP, Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry
disease. Front Genet 2024;15:1395287. DOI PubMed PMC
48. Nowak A, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F. Fabry disease genotype, phenotype, and migalastat
amenability: insights from a national cohort. J Inherit Metab Dis 2020;43:326-33. DOI PubMed
49. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts
by an enzyme inhibitor. Nat Med 1999;5:112-5. DOI
50. McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs 2019;79:543-54. DOI
51. Mauer M, Sokolovskiy A, Barth JA, et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry
disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet 2017;54:781-6. DOI PubMed PMC
52. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in
Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017;54:288-96. DOI
53. Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events,
including renal, cardiac and cerebrovascular outcomes. J Med Genet 2023;60:722-31. DOI PubMed PMC
54. Young-Gqamana B, Brignol N, Chang HH, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic
mice and in the plasma of Fabry patients. PLoS One 2013;8:e57631. DOI PubMed PMC
55. Nowicki M, Bazan-Socha S, Błażejewska-Hyżorek B, et al; Polish Fabry Disease Collaborative Group. A review and
recommendations for oral chaperone therapy in adult patients with Fabry disease. Orphanet J Rare Dis 2024;19:16. DOI
56. Shen JS, Busch A, Day TS, et al. Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme
deficiency in Fabry mice. J Inherit Metab Dis 2016;39:293-303. DOI PubMed PMC
57. Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. Pharmacokinetics, pharmacodynamics, and safety of
moss-aGalactosidase A in patients with Fabry disease. J Inherit Metab Dis 2019;42:527-33. DOI PubMed
58. Palaiodimou L, Kokotis P, Zompola C, et al. Fabry disease: current and novel therapeutic strategies. A narrative review. Curr
Neuropharmacol 2023;21:440-56. DOI PubMed PMC
59. Ashe KM, Budman E, Bangari DS, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of
glucosylceramide synthase for Fabry disease. Mol Med 2015;21:389-99. DOI PubMed PMC
60. Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and
tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev 2021;10:86-98. DOI PubMed PMC
61. Deegan PB, Goker-Alpan O, Geberhiwot T, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment
over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab
2023;138:106963. DOI PubMed PMC
62. A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with fabry
disease (CARAT); 2024. NCT05280548. Available from: https://www.clinicaltrials.gov/study/NCT05280548#eligibility [Last
accessed on 19 Nov 2024]
63. A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥ 16 years of
age with fabry disease (PERIDOT); 2024, NCT05206773. Available from: https://www.clinicaltrials.gov/study/NCT05206773?term=
NCT05206773&rank=1 [Last accessed on 19 Nov 2024]
64. Guérard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage
disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis 2017;12:9. DOI PubMed PMC
65. Guérard N, Oder D, Nordbeck P, et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and
pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther 2018;103:703-11. DOI
66. A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat
oral monotherapy in adult subjects with Fabry disease; 2018, NCT03425539. Available from: https://clinicaltrials.gov/study/
NCT03425539?term=%20NCT03425539&rank=1 [Last accessed on 19 Nov 2024]
67. Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 2021;12:1178. DOI PubMed
PMC
68. Ziegler RJ, Yew NS, Li C, et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene
transfer. Hum Gene Ther 1999;10:1667-82. DOI
69. An open-label, phase 1/2a trial of gene therapy 4D-310 in adults with Fabry disease and cardiac involvement; 2022, NCT05629559.
Available from: https://clinicaltrials.gov/study/NCT05629559?term=NCT05629559&rank=1 [Last accessed on 19 Nov 2024]
70. A phase I/II, multicenter, open-label, single-dose, dose-ranging study to assess the safety and tolerability of ST-920, an AAV2/6
human alpha galactosidase a gene therapy, in subjects with Fabry disease (STAAR); 2019, NCT04046224. Available from: https://
clinicaltrials.gov/study/NCT04046224?term=NCT04046224&rank=1 [Last accessed on 19 Nov 2024]
71. A phase 1/2, baseline-controlled, non-randomized, open-label, single-ascending dose study of a novel adeno-associated viral vector
(FLT190) in patients with Fabry disease; 2019, NCT04040049. Available from: https://clinicaltrials.gov/study/NCT04040049?term=